IPSEN S A/S (OTCMKTS:IPSEY) Downgraded by Jefferies Financial Group to “Hold”

IPSEN S A/S (OTCMKTS:IPSEY) was downgraded by equities research analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a note issued to investors on Thursday, The Fly reports.

A number of other research firms have also recently issued reports on IPSEY. ValuEngine upgraded shares of IPSEN S A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. Barclays cut shares of IPSEN S A/S from an “overweight” rating to an “equal weight” rating in a research note on Monday, December 9th. Finally, JPMorgan Chase & Co. cut shares of IPSEN S A/S from a “neutral” rating to an “underweight” rating in a research note on Sunday. One equities research analyst has rated the stock with a sell rating and five have given a hold rating to the company’s stock. The stock presently has an average rating of “Hold”.

OTCMKTS IPSEY opened at $22.91 on Thursday. The stock has a market capitalization of $7.64 billion, a PE ratio of 13.17 and a beta of 0.47. The company has a 50 day moving average price of $23.97 and a two-hundred day moving average price of $26.55. IPSEN S A/S has a 12-month low of $20.58 and a 12-month high of $35.97.


Ipsen SA operates as a pharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rheumatology areas. Its products include Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors; Cabometyx, a tablet formulation of cabozantinib for renal cell carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; and Dysport for motor disorders and muscular spasticity.

Read More: What is a stock buyback?

The Fly

Receive News & Ratings for IPSEN S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN S A/S and related companies with MarketBeat.com's FREE daily email newsletter.